|
Patient Dropouts
|
D010352 |
[Discontinuance of care received by patient(s) due to reasons other than full recovery from the disease.
] |
|
Patient Education as Topic
|
D010353 |
[The teaching or training of patients concerning their own health needs.
] |
|
Patient Escort Service
|
D010354 |
[A special service provided by volunteers to accompany patients who need help in moving about the health facility.
] |
|
Drug Resistance, Multiple, Viral
|
D024921 |
[The ability of viruses to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance phenotype may be attributed to multiple gene mutation.
] |
|
ionylideneethane
|
C495492 |
|
|
(7-benzothiazol-2-yl-9,-didecylfluoren-2-yl)diphenylamine
|
C495493 |
|
|
hydroxymethylbutenyl diphosphate reductase, Lycopersicon esculentum
|
C495494 |
|
|
corsifuran C
|
C495495 |
|
|
corsifuran B
|
C495496 |
|
|
corsifuran A
|
C495497 |
|
|
BCL9L protein, human
|
C495498 |
|
|
Mox2 protein, rat
|
C495490 |
|
|
staphostatin A, Staphylococcus epidermidis
|
C495491 |
|
|
Parotitis
|
D010309 |
[INFLAMMATION of the PAROTID GLAND.
] |
|
Parkinson Disease
|
D010300 |
[A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
] |
|
K6L5WP peptide
|
C495489 |
|
|
Parkinson Disease, Postencephalitic
|
D010301 |
[Parkinsonism following encephalitis, historically seen as a sequella of encephalitis lethargica (Von Economo Encephalitis). The early age of onset, the rapid progression of symptoms followed by stabilization, and the presence of a variety of other neurological disorders (e.g., sociopathic behavior; TICS; MUSCLE SPASMS; oculogyric crises; hyperphagia; and bizarre movements) distinguish this condition from primary PARKINSON DISEASE. Pathologic features include neuronal loss and gliosis concentrated in the MESENCEPHALON; SUBTHALAMUS; and HYPOTHALAMUS. (From Adams et al., Principles of Neurology, 6th ed, p754)
] |
|
Parkinson Disease, Secondary
|
D010302 |
[Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
] |
|
Paromomycin
|
D010303 |
[An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.
] |
|
Paronychia
|
D010304 |
[An inflammatory reaction involving the folds of the skin surrounding the fingernail. It is characterized by acute or chronic purulent, tender, and painful swellings of the tissues around the nail, caused by an abscess of the nail fold. The pathogenic yeast causing paronychia is most frequently Candida albicans. Saprophytic fungi may also be involved. The causative bacteria are usually Staphylococcus, Pseudomonas aeruginosa, or Streptococcus. (Andrews' Diseases of the Skin, 8th ed, p271)
] |
